Galidesivir

N/A

Report date: 2024/04/30 20:00:07
NME

Base Information

Drug NameGalidesivir
Drug Alias Namegalidesivirum伽利德韦加利司韦galidesivirImmucillin A +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRNA-directed RNA polymerase inhibitors
TargetsRNA-directed RNA polymerase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Filoviridae InfectionsMarburg Virus Disease +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomBrazil
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiocryst Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiocryst Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Filoviridae InfectionsMarburg Virus Disease +[5] 

Other Information

ATC CodeN/A
Related LinksN/A